Our lead candidate is the first in class and best in class pan-FLT3/IRAK4 inhibitor in development for the treatment of AML. 

We are currently evaluating ZE46-0134 in a Phase 1 dose escalation healthy volunteer study.  For more information visit clinicaltrials.gov (XXXXX).